{"url_path":"/sec/capr/8-k/2026-06-26/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 ****Other Events.  **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/1133869/0001104659-26-078327-index.html","accession_number":"0001104659-26-078327","cik":"0001133869","ticker":"CAPR","issuer_name":"CAPRICOR THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1133869/0001104659-26-078327-index.html","primary_entity_key":"0001133869","primary_entity_name":"CAPRICOR THERAPEUTICS, INC."},"word_count":132,"has_tables":true,"body_markdown":"**Item 8.01****Other Events.  **\n\n​\n\nOn June 26, 2026, Capricor Therapeutics, Inc. (the “Company” or “Capricor”) issued a press release announcing that the Cellular, Tissue, and Gene Therapies Advisory Committee of the U.S. Food and Drug Administration (“FDA”) is planning to convene an Advisory Committee meeting to discuss the Company's Biologics License Application (“BLA”) seeking approval of Deramiocel, an investigational cell therapy for the treatment of Duchenne muscular dystrophy (“DMD”). The date for the Advisory Committee meeting is July 29, 2026, and the meeting will be available for live streaming. The Company's BLA remains on track for a target action date under the Prescription Drug User Fee Act (“PDUFA”) of August 22, 2026.\n\n​\n\nA copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\n\n​"}